MedTrace Logo

A Pilot Study of the Treatment of Central Serous Chorioretinopathy With Ketoconazole

NCT00211393 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2012-10-25

No results posted yet for this study

Summary

The purpose of this study is to determine the effect of an adrenocorticoid antagonist (ketoconazole), 600 mg per day for 4 weeks, in the treatment of patients with central serous chorioretinopathy (CSC).

Conditions

  • Chronic Central Serous Chorioretinopathy

Interventions

DRUG

ketoconazole

600mg. /day for 6 weeks

Sponsors & Collaborators

  • LuEsther T. Mertz Retinal Research Center

    collaborator OTHER

  • Manhattan Eye, Ear & Throat Hospital

    lead OTHER

Principal Investigators

  • K. Bailey Freund, MD · Manhattan Eye, Ear & Throat Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2008-03-31
Completion
2008-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00211393 on ClinicalTrials.gov